Profound Medical

Yahoo Finance • last month

Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian i... Full story

Yahoo Finance • last month

Profound Medical increases private placement to $6.45M

* Profound Medical (NASDAQ: PROF [https://seekingalpha.com/symbol/PROF]) on Wednesday had increased its December 19, 2025, private placement to allow participation by a long-term existing investor, with gross proceeds of up to $6.45M fro... Full story

Yahoo Finance • 2 months ago

Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies f... Full story

Yahoo Finance • 2 months ago

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies f... Full story

Yahoo Finance • 3 months ago

Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies f... Full story

Yahoo Finance • 3 months ago

Profound Medical Reports Strong Third Quarter 2025 Financial Results

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies f... Full story

Yahoo Finance • 3 months ago

شركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية

الاتفاقية تفتح المجال أمام علاجات Profound التي لا تستلزم أي جراحة أو إشعاع لاستئصال الأنسجة المريضة، لتخترق بذلك أكبر سوق للرعاية الصحية في الشرق الأوسط تم الحصول بالفعل على جميع الموافقات التنظيمية اللازمة لاستيراد وبيع تقنيتي الاستئصال... Full story

Yahoo Finance • 3 months ago

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies f... Full story

Yahoo Finance • 3 months ago

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guide... Full story

Yahoo Finance • 4 months ago

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies... Full story

Yahoo Finance • 4 months ago

Profound Medical achieves record prelim revenue for third quarter

* Profound Medical (NASDAQ:PROF [https://seekingalpha.com/symbol/PROF]) announced [https://seekingalpha.com/pr/20256714-profound-medical-achieves-record-preliminary-unaudited-revenue-for-the-2025-third-quarter] on Tuesday preliminary una... Full story

Yahoo Finance • 4 months ago

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies... Full story

Yahoo Finance • 4 months ago

Stifel Financial Corporation's Non-Cumulative Preferred Stock Series D Shares Cross 6% Yield Mark

In trading on Thursday, shares of Stifel Financial Corporation's 4.50% Dep Shares Non-Cumulative Preferred Stock Series D (Symbol: SF.PRD) were yielding above the 6% mark based on its quarterly dividend (annualized to $1.125), with shares... Full story

Yahoo Finance • 4 months ago

Profound Medical rises as TULSA procedure launched at Dallas Medical Center

[US Dollar Up Trend with Green Arrows] asbe * Shares of Profound Medical (NASDAQ:PROF [https://seekingalpha.com/symbol/PROF]) traded higher after the company announced that Dallas Medical Center is launching the TULSA procedure, a minim... Full story

Yahoo Finance • 4 months ago

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, incision-free therapies for ablating diseased tissu... Full story

Yahoo Finance • 5 months ago

Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the abl... Full story

Yahoo Finance • 6 months ago

Profound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidence

Earnings Call Insights: Profound Medical Corp. (PROF) Q2 2025 MANAGEMENT VIEW * CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to dri... Full story

Yahoo Finance • 6 months ago

Profound Medical Posts Wider Loss in Q2

Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15... Full story

Yahoo Finance • 6 months ago

Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Plant Biotechnology - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Biotechnology Companies Quadrant is a comprehensive industry... Full story

Yahoo Finance • 6 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the abl... Full story